Calypte raises $3m in private money:
This article was originally published in Clinica
Calypte Biomedical has raised $3m following a private placement of over 16 million shares of its stock with two unnamed investors. The Lake Oswego, Oregon-based company said it will use the proceeds for general working capital purposes, as it continues the commercial roll-out of its Aware line of rapid HIV antibody tests. The firm specialises in developing tests that detect sexually transmitted diseases such as HIV, without the need for blood samples.
You may also be interested in...
Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed – is there a risk of delays to these products being able to demonstrate compliance?
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.